Get the Stockscreener App
4.25
0.23%
-0.010
Cytomx Therapeutics Inc stock is traded at $4.25, with a volume of 2.81M.
It is down -0.23% in the last 24 hours and up +11.55% over the past month.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$4.26
Open:
$4.27
24h Volume:
2.81M
Relative Volume:
0.90
Market Cap:
$720.10M
Revenue:
$101.21M
Net Income/Loss:
$-569.00K
P/E Ratio:
-212.50
EPS:
-0.02
Net Cash Flow:
$-56.88M
1W Performance:
-3.19%
1M Performance:
+11.55%
6M Performance:
+71.37%
1Y Performance:
+300.94%
1-Day Range:
$4.21
$4.66
1-Week Range:
$4.07
$4.66
52-Week Range:
$0.40
$4.66
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Name
Cytomx Therapeutics Inc
Sector
Industry
Phone
650.515.3185
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
4.25 | 721.79M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| May-28-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-09-24 | Upgrade | Wedbush | Neutral → Outperform |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Apr-22-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
| Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
| Nov-15-21 | Initiated | BTIG Research | Buy |
| May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-29-21 | Initiated | JP Morgan | Overweight |
| Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-13-19 | Initiated | Mizuho | Buy |
| May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Nov-26-18 | Initiated | Piper Jaffray | Overweight |
| Oct-15-18 | Initiated | Goldman | Neutral |
| Sep-13-18 | Initiated | H.C. Wainwright | Buy |
| Jun-01-18 | Initiated | SunTrust | Buy |
| Jan-05-18 | Initiated | Citigroup | Buy |
| Sep-08-17 | Initiated | Wedbush | Outperform |
| Mar-27-17 | Initiated | H.C. Wainwright | Buy |
| Mar-02-17 | Initiated | Instinet | Buy |
| Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
Cytomx Therapeutics Inc Stock (CTMX) Latest News
CytomX Therapeutics (NASDAQ:CTMX) Hits New 1-Year HighHere's Why - MarketBeat
What drives CytomX Therapeutics Inc stock priceWeekly Market Snapshot & Investor Community Interactions - earlytimes.in
Chart Watch: Is CytomX Therapeutics Inc stock a safe investment in uncertain markets2025 Bull vs Bear & Verified Short-Term Trading Plans - moha.gov.vn
Will CytomX Therapeutics Inc. stock recover faster than peersChart Pattern Recognition & Exceptional Return Stocks - bollywoodhelpline.com
237,081 Shares in CytomX Therapeutics, Inc. $CTMX Acquired by Precision Wealth Strategies LLC - MarketBeat
Inspire Investing LLC Acquires Shares of 522,482 CytomX Therapeutics, Inc. $CTMX - MarketBeat
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
CytomX Therapeutics (STU:6C1) EV-to-OCF : -7.46 (As of Dec. 26, 2025) - GuruFocus
CytomX Therapeutics (NASDAQ:CTMX) Trading Up 5.4%Here's Why - MarketBeat
CytomX Therapeutics: EpCAM Is Back, Now Prove It Holds (Rating Downgrade) (NASDAQ:CTMX) - Seeking Alpha
CTMX (CytomX Therapeutics) EV-to-OCF : -7.47 (As of Dec. 22, 2025) - GuruFocus
CytomX Therapeutics, Inc.(NasdaqGS:CTMX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Analyst Sentiment Remains Bullish on CytomX Therapeutics (CTMX) Amid CX-2051 Therapy Progress - Insider Monkey
Can CytomX Therapeutics Inc. stock sustain free cash flow growthJuly 2025 News Drivers & Weekly High Return Opportunities - ulpravda.ru
Market Outlook: Why CytomX Therapeutics Inc stock could outperform in 2025Buy Signal & Free High Accuracy Swing Entry Alerts - moha.gov.vn
Sell Signal: Will CytomX Therapeutics Inc stock recover faster than peersJuly 2025 Summary & High Return Trade Guides - moha.gov.vn
Is CytomX Therapeutics Inc. stock a top pick in earnings seasonPortfolio Update Report & Expert Verified Stock Movement Alerts - Улправда
How CytomX Therapeutics Inc. stock trades during market volatilityJuly 2025 Update & Fast Gain Swing Trade Alerts - Улправда
Is CytomX Therapeutics Inc. (6C1) stock undervalued by metricsJuly 2025 Sentiment & Community Trade Idea Sharing Platform - Улправда
Is CytomX Therapeutics Inc. stock gaining market share2025 Geopolitical Influence & Technical Pattern Recognition Alerts - Улправда
Is CytomX Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 PreEarnings & AI Driven Price Forecasts - DonanımHaber
CytomX Therapeutics' (NASDAQ:CTMX) earnings growth rate lags the 256% return delivered to shareholders - simplywall.st
Pullback Watch: What market sentiment indicators show for CytomX Therapeutics Inc. (6C1) stockMarket Performance Recap & Long-Term Safe Investment Plans - Улправда
Aug Opening: Is CytomX Therapeutics Inc. stock gaining market shareJuly 2025 PostEarnings & AI Enhanced Trading Alerts - Улправда
Will CytomX Therapeutics Inc. stock split attract more investorsBuy Signal & Expert-Curated Trade Recommendations - Улправда
CytomX Therapeutics (NASDAQ:CTMX) Trading Down 3.5%What's Next? - MarketBeat
Market Overview: Will CytomX Therapeutics Inc. stock split attract more investorsTake Profit & Fast Momentum Stock Entry Tips - Улправда
CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling - Seeking Alpha
CytomX Therapeutics2025 Funding Rounds & List of Investors - Tracxn
5,769,230 Shares in CytomX Therapeutics, Inc. $CTMX Acquired by Vivo Capital LLC - MarketBeat
Can CytomX Therapeutics Stock Recover If Markets Fall? - Trefis
What analysts say about CytomX Therapeutics Inc stockVolume Weighted Average Price & Explosive Profit Potential - earlytimes.in
With CytomX Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
What Analysts Think Is Changing the CytomX Therapeutics Story After Recent Cancer Developments - Yahoo Finance
CytomX Therapeutics stock maintains Buy rating at H.C. Wainwright ahead of key data By Investing.com - Investing.com South Africa
CytomX Therapeutics stock maintains Buy rating at H.C. Wainwright ahead of key data - Investing.com UK
Is CytomX Therapeutics Inc. stock a contrarian buyJuly 2025 PostEarnings & Technical Confirmation Alerts - Newser
Will CytomX Therapeutics Inc. stock beat EPS estimatesMarket Performance Report & Reliable Breakout Forecasts - Newser
Is CytomX Therapeutics Inc. (6C1) stock suitable for passive index funds2025 Earnings Surprises & Safe Entry Momentum Tips - Newser
Why CytomX Therapeutics Inc. (6C1) stock is listed among top recommendationsTrade Entry Report & High Accuracy Trade Alerts - Newser
Is CytomX Therapeutics Inc. (6C1) stock attractive post correctionProduct Launch & Real-Time Stock Movement Alerts - Newser
Published on: 2025-12-04 14:11:00 - Newser
Will CytomX Therapeutics Inc. (6C1) stock sustain dividend payoutsJuly 2025 Sector Moves & Verified Short-Term Plans - Newser
Would You Still Hold CytomX Therapeutics Stock If It Fell Another 30%? - Trefis
CytomX Therapeutics (NASDAQ:CTMX) Trading Down 6.5%What's Next? - MarketBeat
Is CytomX Therapeutics Inc. (6C1) stock ideal for retirement investorsJuly 2025 Patterns & Fast Gain Stock Trading Tips - Newser
What insider purchases suggest about CytomX Therapeutics Inc. (6C1) stockFed Meeting & Fast Gain Stock Trading Tips - Newser
Is CytomX Therapeutics Inc. (6C1) stock a buy on weaknessQuarterly Trade Summary & Fast Entry High Yield Tips - Newser
Will CytomX Therapeutics Inc. (6C1) stock outperform Dow JonesSell Signal & High Return Stock Watch Alerts - Newser
How CytomX Therapeutics Inc. (6C1) stock reacts to weak economy2025 Price Targets & Entry Point Confirmation Alerts - Newser
Cytomx Therapeutics Inc Stock (CTMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):